Barclays PLC Dexcom Inc Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Dexcom Inc stock. As of the latest transaction made, Barclays PLC holds 1,205,846 shares of DXCM stock, worth $92 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

1,205,846

Previous 1,455,473 17.15%

Holding current value

$92 Million

Previous $165 Million 51.01%

% of portfolio

0.02%

Previous 0.05%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	SELL	$64.0 - $116.06 $16 Million - $29 Million	-249,627 Reduced 17.15%	1,205,846 $80.8 Million
Q2 2024 Aug 14, 2024	BUY	$110.31 - $140.45 $19.3 Million - $24.5 Million	174,646 Added 13.64%	1,455,473 $165 Million
Q1 2024 May 15, 2024	BUY	$114.22 - $140.1 $19.5 Million - $23.9 Million	170,755 Added 15.38%	1,280,827 $178 Million
Q4 2023 Feb 15, 2024	BUY	$75.49 - $124.16 $6.68 Million - $11 Million	88,500 Added 8.66%	1,110,072 $138 Million
Q3 2023 Nov 07, 2023	BUY	$86.06 - $137.93 $19.5 Million - $31.3 Million	226,783 Added 28.53%	1,021,572 $95.3 Million
Q2 2023 Aug 03, 2023	BUY	$112.47 - $130.98 $42.2 Million - $49.1 Million	374,840 Added 89.26%	794,789 $102 Million
Q1 2023 May 04, 2023	SELL	$104.0 - $122.92 $18.1 Million - $21.4 Million	-173,975 Reduced 29.29%	419,949 $48.8 Million
Q4 2022 Feb 13, 2023	BUY	$84.98 - $122.67 $12 Million - $17.4 Million	141,639 Added 31.32%	593,924 $67.3 Million
Q3 2022 Nov 03, 2022	BUY	$76.35 - $94.18 $5.58 Million - $6.88 Million	73,084 Added 19.27%	452,285 $36.4 Million
Q2 2022 Aug 12, 2022	BUY	$67.99 - $132.89 $15.4 Million - $30.2 Million	227,155 Added 149.4%	379,201 $28.3 Million
Q1 2022 May 16, 2022	SELL	$94.08 - $130.2 $3.76 Million - $5.21 Million	-39,998 Reduced 20.83%	152,046 $77.8 Million
Q4 2021 Feb 14, 2022	BUY	$129.87 - $162.82 $424,674 - $532,421	3,270 Added 1.73%	192,044 $103 Million
Q3 2021 Nov 09, 2021	BUY	$106.71 - $143.18 $4.37 Million - $5.87 Million	40,984 Added 27.73%	188,774 $103 Million
Q2 2021 Aug 13, 2021	BUY	$80.99 - $107.93 $1.25 Million - $1.67 Million	15,431 Added 11.66%	147,790 $63.1 Million
Q1 2021 May 13, 2021	SELL	$84.79 - $104.74 $3.11 Million - $3.85 Million	-36,731 Reduced 21.72%	132,359 $47.6 Million
Q4 2020 Feb 11, 2021	BUY	$78.0 - $104.5 $3.86 Million - $5.17 Million	49,485 Added 41.37%	169,090 $62.5 Million
Q3 2020 Nov 12, 2020	BUY	$95.51 - $112.95 $2.5 Million - $2.96 Million	26,227 Added 28.09%	119,605 $49.3 Million
Q2 2020 Aug 12, 2020	BUY	$62.68 - $105.34 $3.83 Million - $6.43 Million	61,056 Added 188.9%	93,378 $37.9 Million
Q1 2020 May 13, 2020	SELL	$47.79 - $75.63 $112,927 - $178,713	-2,363 Reduced 6.81%	32,322 $8.7 Million
Q4 2019 Feb 10, 2020	SELL	$36.62 - $57.29 $148,713 - $232,654	-4,061 Reduced 10.48%	34,685 $7.59 Million
Q3 2019 Nov 14, 2019	SELL	$35.53 - $43.8 $8.97 Million - $11.1 Million	-252,429 Reduced 86.69%	38,746 $5.78 Million
Q2 2019 Aug 14, 2019	BUY	$27.84 - $38.92 $6.96 Million - $9.73 Million	250,098 Added 608.85%	291,175 $43.6 Million
Q1 2019 May 15, 2019	SELL	$28.07 - $38.18 $147,788 - $201,017	-5,265 Reduced 11.36%	41,077 $4.89 Million
Q4 2018 Feb 14, 2019	SELL	$26.99 - $37.37 $521,851 - $722,548	-19,335 Reduced 29.44%	46,342 $5.55 Million
Q3 2018 Nov 14, 2018	BUY	$23.35 - $36.72 $213,138 - $335,180	9,128 Added 16.14%	65,677 $9.4 Million
Q2 2018 Aug 14, 2018	BUY	$17.54 - $25.22 $687,971 - $989,204	39,223 Added 226.38%	56,549 $5.37 Million
Q1 2018 May 15, 2018	SELL	$13.06 - $18.54 $132,754 - $188,459	-10,165 Reduced 36.98%	17,326 $1.29 Million
Q4 2017 Feb 14, 2018	BUY	$11.12 - $15.38 $212,781 - $294,296	19,135 Added 229.0%	27,491 $1.58 Million
Q3 2017 Nov 14, 2017	BUY	$11.36 - $18.98 $94,924 - $158,596	8,356	8,356 $409,000

Others Institutions Holding DXCM

# of Institutions

1,013

Shares Held

351M

Call Options Held

5.51M

Put Options Held

5.6M

View Full List

About DEXCOM INC

Ticker DXCM
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 386,257,984
Market Cap $29.5B
Description
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM ...

More about DXCM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account